Therapeutic Minimal DNA Vectors Carrying Edited Transfer RNAs for Protein Translation
Updated
Abstract
Linear DNA ACE-tRNA vectors as small as 200 bp effectively suppress several nonsense mutations.
- Nonsense mutations, caused by premature termination codons, account for approximately 11% of genetic disease lesions.
- Nonsense suppressor tRNAs have potential as a therapeutic option for rescuing these mutations.
- DNA delivery of ACE-tRNAs offers advantages such as lower manufacturing costs and improved safety compared to viral or RNA-based methods.
- ACE-tRNA minivectors demonstrate better bioavailability, less immune response, and greater stability than traditional plasmid DNA vectors.
Simplified
Funding
Competing interests
DECLARATION OF INTERESTS J.D.L. is a co-inventor of a technology presented in this study and receives royalty payments related to the licensing of the technology from the University of Iowa. PCT/US2018/059065, METHODS OF RESCUING STOP CODONS VIA GENETIC REASSIGNMENT WITH ACE-tRNA; Inventors - University of Iowa – Inventors J.D.L. and Christopher A. Ahern pertains to tRNA sequences used in this study. J.D.L. and J.J.P. are co-inventors of technologies presented in this study that pertains to the optimized tRNA sequences and minivectors used in this study. D.A.D. serves as a member of the Scientific Advisory Board of Seawolf Therapeutics and has equity interest in the company.
PubMed